COMMUNIQUÉS West-GlobeNewswire

Anaptys Announces Participation at Upcoming Investor Conferences
05/02/2026
SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president [...]
Dentsply Sirona to Host Fourth Quarter and Full Year Conference Call on February 26
05/02/2026
CHARLOTTE, N.C., Feb. 05, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will host an investor conference call and live webcast on [...]
Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit
05/02/2026
SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside chat at the [...]
Amwell® to report fourth quarter and full year 2025 operating results
05/02/2026
BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, will report fourth quarter and full year 2025 [...]
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March
05/02/2026
SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the following two upcoming investor conferences: TD Cowen 46 th [...]
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
05/02/2026
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of [...]
Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288
06/02/2026
ROCKVILLE, Md. and SUZHOU, China, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the [...]
Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma
05/02/2026
52% Amtagvi Response Rate with Two or Fewer Prior Lines of Therapy 73% Overall Disease Control Rate SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial [...]
His Choice Health Announces Opening of New Charlotte Clinic, Expanding Access to Trusted, Patient-Centered Men’s Health Care
06/02/2026
Regional Growth Following Raleigh–Durham Brand Unification CHARLOTTE, NC, Feb. 05, 2026 (GLOBE NEWSWIRE) -- His Choice Health today announced the upcoming opening of its newest clinic in Charlotte, targeted late [...]
Surrozen to Present at Upcoming Healthcare Investor Conference
05/02/2026
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling [...]
Renaissance Recovery’s Award-Winning Drug and Alcohol Rehab Center Launches New 10,000 Sq. Ft. Expansion in Nashville, Tennessee
05/02/2026
NASHVILLE, Tenn., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Renaissance Recovery, a District Behavioral Health Group (DBH) company, announced today the opening of its newest expansion in Nashville, Tennessee. As an award- [...]
Teknova to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
05/02/2026
HOLLISTER, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, [...]
Seer to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
05/02/2026
REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the [...]
Biotricity to Announce Continued Growth in Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11th
05/02/2026
Company continues to drive Revenue Growth, Margin Strength, Operational Efficiency, and continued positive EBITDA REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative [...]
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026
05/02/2026
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE [...]
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/02/2026
WESTLAKE VILLAGE, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, [...]
BioPorto provides Preliminary Unaudited 2025 Financial Figures, Financial Guidance for 2026 and a Business Update
05/02/2026
February 5, 2026 Announcement no. 1 BioPorto provides Preliminary Unaudited 2025 Financial Figures, Financial Guidance for 2026 and a Business Update COPENHAGEN, DENMARK, February 5, 2026, (GLOBE NEWSWIRE) – BioPorto A/ [...]
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
05/02/2026
Bagsværd, Denmark, 5 February 2026 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance [...]
Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™
05/02/2026
Analysis from continued follow-up of Phase 1/2 clinical trial data in Hunter syndrome (MPS II) reinforces potential for tividenofusp alfa (DNL310) to address full disease spectrum Launch readiness established in [...]

Pages